[Anti-Prostate Cancer Activity of Survivin-T34A Mutant in Vitro and in Vivo].

Li Pan,Xing-Chen Peng,Qing-Zhong Yuan,Fei Leng,Dan-Dan Yu,Yan Shan,Zhi-Yong Li,Chun-Ting Wang

DOI: https://doi.org/10.3969/j.issn.1672-173x.2010.03.004

2010-01-01

Abstract:OBJECTIVETo investigate the effect of Survivin-T34A mutant on murine prostate cancer and its apoptosis-inducing efficacy in vivo and in vitro.METHODSIn vitro, prostate cancer cells TRAMP-C1 were transfected with Survivin-T34A plasmid encapsulated by cationic liposome. The apoptosis of TRAMP-C1 was evaluated with flow cytometry. C57BL/6 mice model with TRAMP-C1 prostate cancer was established. Twenty four male mice with TRAMP-C1 prostate cancers were divided randomly into three groups, which were intravenously injected with normal saline, empty vector PORF-9-null encapsulated by cationic liposome and Survivin-T34A plasmid encapsulated by cationic liposome respectively twice a week for eight doses. The size of tumors was measured and the tumor sections of each group were stained with TUNEL reagent for apoptosis detection.RESULTSAn apoptotic index of 46% of TRAMP-C1 transfected with Survivin-T34A plasmid encapsulated by cationic liposome was observed. The tumor volume of Survivin-T34A group of C57BL/6 mice with TRAMP-C1 prostate cancer was far smaller than those in the control groups (P < 0.05) and the tumors treated with Survivin-T34A showed significant increase of apoptosis compared with those of control groups (P < 0.05).CONCLUSIONSurvivin-T34A mutant efficiently inhibits the growth of prostate cancer, which is based on the mechanism of Survivin-T34A mutant inducing apoptosis of tumor cells.